Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
Stem Cell Transplant Into Airways Might Treat CF, Mouse Study Suggests
on August 16, 2018 at 5:14 am
A study in mice showed it is possible to transplant stem cells into the lungs and replenish the airways with healthy cells, an approach that could combat cystic fibrosis and alleviate its symptoms. Re... […]
Hematopoietic Stem Cell Transplantation (HSCT) Market Trends, Outlook, and Opportunity Analysis, 2018 - 2026
on August 10, 2018 at 10:43 am
Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a pa... […]
Trial will test stem cell transplant for Crohn’s disease
on August 9, 2018 at 2:19 pm
A new trial led by researchers from Queen Mary University of London and Barts Health NHS Trust, as well as other institutions in the United Kingdom, will investigate a therapy that attempts to restart ... […]
Patient-Reported Outcomes With Stem Cell Transplant Signal Progress in Myeloma
on August 8, 2018 at 9:02 am
Preliminary pilot data presented at the 2018 ASCO Annual Meeting suggest that autologous stem cell transplant (ASCT) does not impair short-term cognition, function, or symptoms of patients with newly ... […]
Rebooting the immune system with stem cell transplants trialed for Crohn's disease
on August 6, 2018 at 8:02 pm
A large trial has just been launched in the UK exploring the use of stem cells for treating patients with Crohn's disease. The radical treatment involves essentially "rebooting" a patient's immune sys... […]
Could stem cell transplants cure Crohns disease?
on August 6, 2018 at 1:18 pm
A new trial is underway to test whether stem cell transplants could put an end to Crohn’s disease. 115,000 people in this country alone have the chronic condition – an inflammation of the gut which ca... […]
Stem cell transplants to be used in treating Crohn’s disease
on August 6, 2018 at 2:12 am
[email protected] receives funding from the Medical Research Council, The National Institute of Health Research, Crohn's and Colitis UK, The Barts Charity, Bowel and Cancer Research, Th... […]
Clinical trial to use stem cell transplants for treating Crohn's disease
on August 6, 2018 at 12:11 am
A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at leas... […]
Zithromax FDA warning: Increased risk of cancer relapse with long-term use after Donor Stem Cell Transplant
on August 4, 2018 at 5:41 am
The Food and Drug Administration (FDA) issued a warning Friday concerning the long-term use of azithromycin (Zithromax, Zmax) for prophylaxis of bronchiolitis obliterans syndrome to patients who under... […]
New Research Opens Door to Expanding Stem Cells Available for Transplants
on August 4, 2018 at 2:57 am
This may also be complementary to the approach of haploidentical adult stem cell transplants, which involve donors from a close but still mismatched family member. These patients typically require imm... […]
via Google News and Bing News